GenScript ProBio
Latest round
- Series C
Last raised
- Apr 2023
Total raised
- $374M
Investors
- 11
About GenScript ProBio
Established in 2021 and based in Nanjing, China, GenScript ProBio is a subsidiary of GenScript Biotech Corporation. The company was established as a CDMO platform integrating discovery, pre-clinical, and clinical development services for biologics and gene therapies. It has expanded operations globally with branches in the United States, the Netherlands, South Korea, Hong Kong, and Nanjing. Approximately half of its core research team holds doctoral degrees. The company’s CEO, Husheng Min, formerly served as Chief Scientist at Amgen and led the establishment of Samsung Bio. In November 2021, its Nanjing antibody-protein production site passed the EU Qualified Person (QP) quality audit, and in May 2022, the company entered into a partnership with Athenex. To date, GenScript ProBio has supported more than 90 investigational new drug (IND) approvals across the United States, Europe, and Asia Pacific. The company provides biopharmaceutical CDMO services for cell and gene therapy (CGT) drugs, vaccine and biologic drug discovery and antibody-protein drugs. CDMO services include cell line and analytical method development, host cell commercialization licensing, upstream and downstream process development, and clinical sample and commercial production. Its solutions include cell and gene therapy solutions, and biologics development solutions. Cell and gene therapy solutions include plasmid clinical, mRNA, lentivirus and adeno-associated virus filing total solutions, and linearized plasmids and mRNA production. The company generates revenue through CDMO contracts, including process development, clinical material production, and commercial manufacturing services for global pharmaceutical and biotechnology clients. GenScript ProBio plans to expand its global GMP manufacturing capacity, strengthen its integrated CMC solutions, and accelerate partnerships in antibody, vaccine and gene therapy development.
Who invested in GenScript ProBio
11 investors across 2 rounds
See all investors in GenScript ProBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GenScript ProBio
Who invested in GenScript ProBio?
GenScript ProBio has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GenScript ProBio raised?
GenScript ProBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did GenScript ProBio last raise money?
GenScript ProBio's most recent round on record is a Series C, in Apr 2023.
What does GenScript ProBio do?
Established in 2021 and based in Nanjing, China, GenScript ProBio is a subsidiary of GenScript Biotech Corporation.
Where is GenScript ProBio headquartered?
GenScript ProBio is headquartered in Nanjing, China.
Which VCs invest in companies like GenScript ProBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at GenScript ProBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like GenScript ProBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.